Given the aggressive nature and poor prognosis of both adult and pediatric high-grade gliomas (HGG), identifying ALT activation through functional testing could have dual value, serving not only as diagnostic tool but also as theranostic marker, guiding patients toward emerging ALT-targeted therapies. The gene discussed is GPT; the disease is malignant glioma.